Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease

Journal of Cardiovascular Medicine

Volumn 16, Issue 1, 2015, Pages 29-36

  Maiolino, Giuseppe ^a   Lenzini, Livia ^a   Pedon, Luigi ^b   Cesari, Maurizio ^a   Seccia, Teresa Maria ^a   Frigo, Anna Chiara ^c   Rossitto, Giacomo ^a   Caroccia, Brasilina ^a   Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Ospedale di Cittadella   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atherosclerosis; Coronary artery disease; Lipoprotein associated phospholipase a2; Prognosis; Single nucleotide polymorphism

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; PLA2G7 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COMPLICATION; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; CORONARY ARTERY DISEASE; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84918837153     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000057     Document Type: Article

References (48)

1. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of plateletactivating- factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261:511-514.
2. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338:479-487.
3. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcho line, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138-1144.
4. Inoue N, Takeshita S, Gao D, et al. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 2001; 155:45-52.
5. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002; 161:387-394.
6. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150:209-216.
7. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994->T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47:177- 181.
8. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279->Phe) is a genetic risk factor for stroke. Stroke 1997; 28:2417-2420.
9. Ichihara S, Yamada Y, Yokota M. Association of a G994->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 1998; 98:1881-1885.
10. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-2791.
11. Miwa M, Miyake T, Yamanaka T, et al. Characterization of serum plateletactivating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82:1983-1991.
12. Jang Y, Kim OY, Koh SJ, et al. The Val279Phe variant of the lipoproteinassociated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006; 91:3521-3527.
13. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
14. Maiolino G, Pedon L, Cesari M, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One 2012; 7:e48171.
15. Sutton BS, Crosslin DR, Shah SH, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet 2008; 17:1318-1328.
16. Liu PY, Li YH, Wu HL, et al. Platelet-activating factor-acetylhydrolase A379 V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost 2006; 4:1023-1028.
17. De Caterina R, Talmud PJ, Merlini PA, et al. Gruppo Italiano Aterosclerosi. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis 2011; 214:397-403.
18. Hoffmann MM, Winkler K, Renner W, et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 2009; 7:41-48.
19. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ, HIFMECH Study Group. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 2003; 168:283-288.
20. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factoracetylhydrolase and PAF-receptor gene haplo types in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 2004; 13:1341-1351.
21. Wootton PT, Stephens JW, Hurel SJ, et al. Lp-PLA2 activity and PLA2G7 A379 V genotype in patients with diabetes mellitus. Atherosclerosis 2006; 189:149-156.
22. Grallert H, Dupuis J, Bis JC, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 2012; 33:238-251.
23. Casas JP, Ninio E, Panayiotou A, et al. PLA2G7 genotype, lipoproteinassociated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010; 121:2284-2293.
24. Rosenbaum PR, RDB. Reducing bias in observational studies using sub classification on the propensity score. J Am Stat Assoc 1984; 79:516- 524.
25. Rossi GP, Cesari M, De Toni R, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003; 108:2467-2472.
26. Rossi GP, Cesari M, Zanchetta M, et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003; 41:930-937.
27. Cesari M, Pessina AC, Zanchetta M, et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in highrisk nondiabetic patients. J Intern Med 2006; 260:474-483.
28. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996; 27:1007-1019.
29. Maiolino G, Cesari M, Sticchi D, et al. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008; 93:3333-3340.
30. Rossi GP, Maiolino G, Seccia TM, et al. Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. J Hypertens 2006; 24:851-859.
31. Rossi GP, Maiolino G, Zanchetta M, et al. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol 2006; 48:1166-1174.
32. Tabachnick BG, Fidell LS, editors. Using multivariate statistics. 4th ed. Boston, MA: Allyn & Bacon; 2001.
33. Maiolino G, Pedon L, Cesari M, et al. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. Int J Cardiol 2013; 168:484-489.
34. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009; 51:171-184.
35. Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011; 32:1704-1708.
36. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer Verlag; 1997.
37. Barrett JC, Fry B, Maller J, Daly MJ. Haplo view: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
38. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56-62.
39. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157-1166.
40. Hou L, Chen S, Yu H, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009; 125:11-20.
41. Jang Y, Waterworth D, Lee JE, et al. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLoS One 2011; 6:e18208.
42. Li L, Qi L, Lv N, et al. Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population. Ann Hum Genet 2011; 75:605-611.
43. Koh JS, Park JH, Shin DH, et al. Risk factors and effects on long-term outcomes of cardiac troponin I elevation after drug-eluting stent implantation in patients with stable coronary artery disease. Am J Cardiol 2012; 109:461-465.
44. Vlek AL, van der Graaf Y, Sluman MA, Moll FL, Visseren FL, SMART Study Group. Metabolic syndrome and vascular risk in patients with peripheral arterial occlusive disease. J Vasc Surg 2009; 50:61-69.
45. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. The effect of clinical characteristics and dietary habits on the relationship between education status and 5-year incidence of cardiovascular disease: the ATTICA study. Eur J Nutr 2008; 47:258-265.
46. Suchindran S, Rivedal D, Guyton JR, et al. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 2010; 6:e1000928.
47. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010; 160:655-661.
48. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011; 162:613-619; e1.